Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors
Ovarian cancer is the most important cause of gynecological cancer-related mortality, with the majority of women presenting with advanced disease. Although surgery and chemotherapy can improve survival rates, it is necessary to integrate alternative strategies to improve the outcomes. Advances in un...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2015/191832 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556476242067456 |
|---|---|
| author | Francesca De Felice Claudia Marchetti Innocenza Palaia Daniela Musio Ludovico Muzii Vincenzo Tombolini Pierluigi Benedetti Panici |
| author_facet | Francesca De Felice Claudia Marchetti Innocenza Palaia Daniela Musio Ludovico Muzii Vincenzo Tombolini Pierluigi Benedetti Panici |
| author_sort | Francesca De Felice |
| collection | DOAJ |
| description | Ovarian cancer is the most important cause of gynecological cancer-related mortality, with the majority of women presenting with advanced disease. Although surgery and chemotherapy can improve survival rates, it is necessary to integrate alternative strategies to improve the outcomes. Advances in understanding the role of immune system in the pathogenesis of cancer have led to the rapid evolvement of immunotherapy, which might establish a sustained immune system response against recurring cancer cells. Recently, it has emerged that powerful immunologic effector cells may be blocked by inhibitory regulatory pathways controlled by specific molecules often called “immune checkpoints,” which turn off the immune system. Similarly, cancer cells are able to use these checkpoints to avoid immune control and rejection. Inhibition of these inhibitory pathways represents a potent strategy in the fight against cancer and is currently under investigation with encouraging results in some cancers, such as melanoma. In ovarian cancer researches are still in an early phase, but with promising results. In this review we will explore the rationale of immunotherapy in ovarian cancer with a special focus on these emerging molecules. |
| format | Article |
| id | doaj-art-7771f21bbcc44161b5aca7a5e2443112 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-7771f21bbcc44161b5aca7a5e24431122025-02-03T05:45:18ZengWileyJournal of Immunology Research2314-88612314-71562015-01-01201510.1155/2015/191832191832Immunotherapy of Ovarian Cancer: The Role of Checkpoint InhibitorsFrancesca De Felice0Claudia Marchetti1Innocenza Palaia2Daniela Musio3Ludovico Muzii4Vincenzo Tombolini5Pierluigi Benedetti Panici6Department of Radiotherapy, Policlinico Umberto I, “Sapienza” University of Rome, Viale Regina Elena 326, 00161 Rome, ItalyDepartment of Gynecological and Obstetrical Sciences and Urological Sciences, “Sapienza” University of Rome, Viale del Policlinico 155, 00161 Rome, ItalyDepartment of Gynecological and Obstetrical Sciences and Urological Sciences, “Sapienza” University of Rome, Viale del Policlinico 155, 00161 Rome, ItalyDepartment of Radiotherapy, Policlinico Umberto I, “Sapienza” University of Rome, Viale Regina Elena 326, 00161 Rome, ItalyDepartment of Gynecological and Obstetrical Sciences and Urological Sciences, “Sapienza” University of Rome, Viale del Policlinico 155, 00161 Rome, ItalyDepartment of Radiotherapy, Policlinico Umberto I, “Sapienza” University of Rome, Viale Regina Elena 326, 00161 Rome, ItalyDepartment of Gynecological and Obstetrical Sciences and Urological Sciences, “Sapienza” University of Rome, Viale del Policlinico 155, 00161 Rome, ItalyOvarian cancer is the most important cause of gynecological cancer-related mortality, with the majority of women presenting with advanced disease. Although surgery and chemotherapy can improve survival rates, it is necessary to integrate alternative strategies to improve the outcomes. Advances in understanding the role of immune system in the pathogenesis of cancer have led to the rapid evolvement of immunotherapy, which might establish a sustained immune system response against recurring cancer cells. Recently, it has emerged that powerful immunologic effector cells may be blocked by inhibitory regulatory pathways controlled by specific molecules often called “immune checkpoints,” which turn off the immune system. Similarly, cancer cells are able to use these checkpoints to avoid immune control and rejection. Inhibition of these inhibitory pathways represents a potent strategy in the fight against cancer and is currently under investigation with encouraging results in some cancers, such as melanoma. In ovarian cancer researches are still in an early phase, but with promising results. In this review we will explore the rationale of immunotherapy in ovarian cancer with a special focus on these emerging molecules.http://dx.doi.org/10.1155/2015/191832 |
| spellingShingle | Francesca De Felice Claudia Marchetti Innocenza Palaia Daniela Musio Ludovico Muzii Vincenzo Tombolini Pierluigi Benedetti Panici Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors Journal of Immunology Research |
| title | Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors |
| title_full | Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors |
| title_fullStr | Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors |
| title_full_unstemmed | Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors |
| title_short | Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors |
| title_sort | immunotherapy of ovarian cancer the role of checkpoint inhibitors |
| url | http://dx.doi.org/10.1155/2015/191832 |
| work_keys_str_mv | AT francescadefelice immunotherapyofovariancancertheroleofcheckpointinhibitors AT claudiamarchetti immunotherapyofovariancancertheroleofcheckpointinhibitors AT innocenzapalaia immunotherapyofovariancancertheroleofcheckpointinhibitors AT danielamusio immunotherapyofovariancancertheroleofcheckpointinhibitors AT ludovicomuzii immunotherapyofovariancancertheroleofcheckpointinhibitors AT vincenzotombolini immunotherapyofovariancancertheroleofcheckpointinhibitors AT pierluigibenedettipanici immunotherapyofovariancancertheroleofcheckpointinhibitors |